Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.61 |
| ▸ | HPGD | P15428 | 10/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.51 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | UBE2I | P63279 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28619469 | 0.84 | ALDH1A1 (0.58) | ALDH1A1HPGDKDM4ELMNAMAPT | |
| SCHEMBL15131272 | 0.84 | ALDH1A1 (0.58) | ALDH1A1HPGDKDM4ELMNAMAPT | |
| SCHEMBL6038446 | 0.81 | ALDH1A1 (0.42) | ALDH1A1HPGDKDM4ELMNAMAPT | |
| SCHEMBL840296 | 0.80 | ALDH1A1 (0.55) | ALDH1A1HPGDKDM4ELMNAMAPT | |
| SCHEMBL6753961 | 0.80 | ALDH1A1 (0.55) | ALDH1A1HPGDKDM4ELMNAMAPT | |
| SCHEMBL23722477 | 0.80 | ALDH1A1 (0.55) | ALDH1A1HPGDKDM4ELMNAMAPT | |
| SCHEMBL14036839 | 0.80 | ALDH1A1 (0.42) | ALDH1A1HPGDKDM4ELMNAMAPT | |
| SCHEMBL6289739 | 0.80 | ALDH1A1 (0.55) | ALDH1A1HPGDKDM4ELMNAMAPT | |
| SCHEMBL7474156 | 0.79 | ALDH1A1 (0.46) | ALDH1A1HPGDKDM4ELMNAMAPT | |
| SCHEMBL1081928 | 0.79 | ALDH1A1 (0.59) | ALDH1A1HPGDKDM4ELMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6946253-B2 | Herpes zinc finger motifs | UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) | 2005-09-20 | — | — | US | claimed |
| US-20030186283-A1 | Herpes zinc finger motifs | UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) | 2003-10-02 | — | — | US | claimed |
| EP-1299725-A2 | HERPES ZINC FINGER MOTIFS | THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) | 2003-04-09 | — | — | EP | claimed |
| WO-2002004492-A2 | HERPES ZINC FINGER MOTIFS | THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) | 2002-01-17 | — | — | WO | claimed |
| US-20250161247-A1 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | LANTERN PHARMA INC. (US) | 2025-05-22 | — | — | US | disclosed |
| WO-2023164293-A1 | METHODS FOR VIRAL INFECTIONS | JERICHO SCIENCES, LLC (US) | 2023-08-31 | — | — | WO | disclosed |
| US-20230134425-A1 | METHODS OF TREATING GLIOBLASTOMA | TRIACT THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-11628144-B2 | Iniparib formulations and uses thereof | TRIACT THERAPEUTICS, INC. (US) | 2023-04-18 | — | — | US | disclosed |
| CN-115911342-A | Silicon negative electrode material, preparation method thereof, negative electrode and lithium ion battery | 江苏中兴派能电池有限公司 | 2023-04-04 | — | — | CN | disclosed |
| US-11433074-B2 | Methods of treating glioblastoma | TRIACT THERAPEUTICS, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-11433075-B2 | Methods of treating glioblastoma | TRIACT THERAPEUTICS, INC. (US) | 2022-09-06 | — | — | US | disclosed |
| US-20210137929-A1 | METHODS OF TREATING GLIOBLASTOMA | TRIACT THERAPEUTICS, INC. | 2021-05-13 | — | — | US | disclosed |
| US-5473074-A | Destabilize protein domains capable of binding zinc atoms | OCTAMER, INCORPORATED (US) | 1995-12-05 | — | — | US | disclosed |
| EP-0666742-A1 | ADENOSINE DIPHOSPHORIBOSE POLYMERASE BINDING NITROSO AROMATIC COMPOUNDS USEFUL AS ANTI-RETROVIRAL AGENTS AND ANTI-TUMOR AGENTS | OCTAMER, INC. (US) | 1995-08-16 | — | — | EP | disclosed |
| EP-0609211-A4 | ADENOSINE DIPHOSPHORIBOSE POLYMERASE BINDING NITROSO AROMATIC COMPOUNDS USEFUL AS ANTI-TUMOR AND ANTI-RETROVIRAL AGENTS. | OCTAMER INC (US) | 1995-02-01 | — | — | EP | disclosed |
| WO-1994019331-A1 | ORTHO-SUBSTITUTED 2-METHOXYIMINOPHENYLACETIC ACID METHYLAMIDES | BASF AKTIENGESELLSCHAFT (DE) | 1994-09-01 | — | — | WO | disclosed |
| EP-0609211-A1 | ADENOSINE DIPHOSPHORIBOSE POLYMERASE BINDING NITROSO AROMATIC COMPOUNDS USEFUL AS ANTI-TUMOR AND ANTI-RETROVIRAL AGENTS | OCTAMER, INC. (US) | 1994-08-10 | — | — | EP | disclosed |
| WO-1994009776-A1 | ADENOSINE DIPHOSPHORIBOSE POLYMERASE BINDING NITROSO AROMATIC COMPOUNDS USEFUL AS ANTI-RETROVIRAL AGENTS AND ANTI-TUMOR AGENTS | OCTAMER, INC. (US) | 1994-05-11 | — | — | WO | disclosed |
| US-5262564-A | Anticarcinogenic agents | OCTAMER, INC. (US) | 1993-11-16 | — | — | US | disclosed |
| WO-1993007868-A1 | ADENOSINE DIPHOSPHORIBOSE POLYMERASE BINDING NITROSO AROMATIC COMPOUNDS USEFUL AS ANTI-TUMOR AND ANTI-RETROVIRAL AGENTS | OCTAMER, INC. (US) | 1993-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161247-A1 | METHOD FOR TREATING BREAST CANCERS AND PARP RESISTANT BREAST CANCERS | PARP1, PARP2, PARP3 | ALDH1A1 1781/4885HPGD 1833/4885KDM4E 2108/4885 |
| US-20210137929-A1 | METHODS OF TREATING GLIOBLASTOMA | MGMT, IDH3B, IDH3A | ALDH1A1 1863/4885HPGD 911/4885KDM4E 2819/4885 |
| US-20230134425-A1 | METHODS OF TREATING GLIOBLASTOMA | MGMT, IDH3B, IDH3A | ALDH1A1 1863/4885HPGD 911/4885KDM4E 2819/4885 |
| US-11433074-B2 | Methods of treating glioblastoma | MGMT, IDH3B, IDH3A | ALDH1A1 1863/4885HPGD 911/4885KDM4E 2819/4885 |
| US-11628144-B2 | Iniparib formulations and uses thereof | INPP5B, INPPL1, PARP3 | ALDH1A1 1362/4885HPGD 255/4885KDM4E 3120/4885 |
| US-11433075-B2 | Methods of treating glioblastoma | MGMT, IDH3B, IDH3A | ALDH1A1 1863/4885HPGD 911/4885KDM4E 2819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.